India Pharma Outlook Team | Thursday, 05 June 2025
An agreement has been reached between BioNTech and Bristol Myers Squibb for the worldwide co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across a variety of solid tumor types. The agreement calls for BioNTech and BMS to collaborate in order to expand and expedite the development of this clinical candidate.
More than 1,000 patients have received treatment from BioNTech's BNT327, a next-generation bispecific antibody candidate that targets PD-L1 and VEGF-A. These trials include international Phase 3 trials with registrational potential that assess BNT327 as a first-line theraphy for non-small cell lung cancer (NSCLC) and extensive stage small cell lung cancer (ES-SCLC).
By the end of 2025, a global Phase 3 study assessing the candidate in triple negative breast cancer (TNBC) is anticipated to begin. The combination of anti-PD-L1 and anti-VEGF-A, two well-established therapeutic targets, into a single molecule has the potential to provide synergistic clinical advantages for patients with a variety of tumor types, according to preliminary findings from ongoing trials.
Also read:FDA Approves J&J's Rybrevant Combo for NSCLC with EGFR Exon 20 Insertions
"We believe BNT327 has the potential to become a foundational immuno-oncology backbone, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid-tumor indications. Our collaboration with BMS, a pioneering leader in immuno-oncology, aims to accelerate and broadly expand BNT327’s development to fully realize its potential,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “Our focus remains on advancing high-impact, pan-tumor programs and combination strategies in oncology, with BNT327 complementing our antibody-drug conjugate programs and mRNA-based immunotherapies. We are dedicated to delivering truly transformative options for patients in need.
, CDSCO.jpg)
